- Home
- News
News about CCII and Cancer Immunotherapy
Find out what is happening at CCII and in the field of cancer immunotherapy. Here we share the latest news about research at CCII and the CCII research community and about trends in immunology and cancer research.
Featured News
Spermidine to the Rescue?
Spermidine, a polyamine compound found in ribosomes and living tissues and originally isolated from semen, is an increasingly popular anti-aging supplement. Muna Al-Habsi and her colleagues demonstrate in a new paper published in Science that spermidine can enhance cancer immunotherapy blocking the PD-1 pathway by reversing aging effects in killer T-cells.
All News
-
Design for Science
CCII's new home, the “Bristol Myers Squibb Building” at the Kyoto University campus, has been made possible by funding from the Japanese government and a generous donation from pharmaceutical giant Bristol Myers Squibb.
More
-
1st Meeting of the Kyoto University Tumor Immunology Study Group
This study group serves as a platform to foster interdisciplinary collaboration, bringing together researchers and clinicians engaged in cancer immunology.
More
-
[CLOSED] Call for Applications: Associate Professor Position within the CCII Informatics Platform Team
This Call for Applications is now closed, but we are permanently recruiting. Please contact us!
More
-
[CLOSED] Call for Applications: Professor Position in the Division of Cancer Immune Regulation
This Call for Applications is now closed, but we are permanently recruiting. Please contact us!
More
-
Donation from JCR Pharma Ltd.
Donation from JCR Pharma Ltd. to the "Tasuku Honjo Volunteer Fund" and the "Cancer Immunotherapy Research Fund" through a third-party allocation of treasury shares.
More